INDEMNIFICATION AGREEMENTIndemnification Agreement • June 3rd, 2016 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of , 20 by and between Syros Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
SYROS PHARMACEUTICALS, INC. Incentive Stock Option Agreement Granted Under 2012 Equity Incentive PlanIncentive Stock Option Agreement • June 3rd, 2016 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations
SYROS PHARMACEUTICALS, INC. Nonstatutory Stock Option Agreement Granted Under 2012 Equity Incentive PlanNonstatutory Stock Option Agreement • June 3rd, 2016 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations
SYROS PHARMACEUTICALS, INC. Restricted Stock Agreement Granted Under 2012 Equity Incentive PlanRestricted Stock Agreement • June 3rd, 2016 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
SYROS PHARMACEUTICALS, INC. INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • June 3rd, 2016 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations
This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
SYROS PHARMACEUTICALS, INC. NONSTATUTORY STOCK OPTION AGREEMENTNonstatutory Stock Option Agreement • June 3rd, 2016 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations
This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
SYROS PHARMACEUTICALS, INC. SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTRights Agreement • June 3rd, 2016 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT is made as of the 9th day of October, 2014, by and among Syros Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” and any Additional Purchaser (as defined in the Purchase Agreement (as defined below)) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH and DANA-FARBER CANCER INSTITUTE, INC. and SYROS PHARMACEUTICALS, INC....Patent License Agreement • June 3rd, 2016 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Agreement, effective as of April 1, 2013 (the “EFFECTIVE DATE”), is among the Whitehead Institute for Biomedical Research (“WHITEHEAD”), a Delaware corporation, having a principal office at Nine Cambridge Center, Cambridge, MA 02142; the Dana-Farber Cancer Institute, Inc. (“DFCI”), a Massachusetts non-profit organization having a principal place of business at 450 Brookline Ave., Boston, MA 02215; and Syros Pharmaceuticals, Inc. (“COMPANY”), a Delaware corporation, having a principal place of business at 480 Arsenal Street, Suite 130, Watertown, MA 02472.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. CANCER LICENSE AGREEMENTCancer License Agreement • June 3rd, 2016 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS CANCER LICENSE AGREEMENT (this “Agreement”) dated as of September 11, 2015 (the “Effective Date”) is entered into between TMRC Co., Ltd., a Japanese corporation having a place of business at 1-12-12, Kita Shinjuku, Shinjuku-ku, Tokyo 164-0074, Japan (“TMRC”) and Syros Pharmaceuticals, Inc., a Delaware corporation having a place of business at 620 Memorial Drive, Suite 300, Cambridge MA 02139 USA (“Syros”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. DANA-FARBER CANCER INSTITUTE, INC. and SYROS PHARMACEUTICALS, INC. LICENSE AGREEMENTLicense Agreement • June 3rd, 2016 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Agreement, effective as of February 22, 2013 (the “EFFECTIVE DATE”), is between the Dana-Farber Cancer Institute, Inc. (“DFCI”), a Massachusetts non-profit organization having a principal place of business at 450 Brookline Ave., Boston, MA 02215 and Syros Pharmaceuticals, Inc. (“COMPANY”), a Delaware corporation, having a principal place of business at 1 Memorial Drive, Seventh Floor, Cambridge MA 02142.
SUPPLY MANAGEMENT AGREEMENTSupply Management Agreement • June 3rd, 2016 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS SUPPLY MANAGEMENT AGREEMENT (this “Agreement”) dated as of April 28, 2016 (the “Effective Date”) is entered into between Syros Pharmaceuticals, Inc., a Delaware corporation having an office and place of business at 620 Memorial Drive, Suite 300, Cambridge MA 02139 USA (“Syros”), and TMRC Co., Ltd., a Japanese corporation having an office and place of business at 1-12-12, Kita Shinjuku, Shinjuku-ku, Tokyo, 164-0074, Japan (“TMRC”). Syros and TMRC are individually referred to as a “Party” and collectively, Syros and TMRC are referred to as the “Parties”.
Consent and Stand-by License AgreementConsent and Stand-by License Agreement • June 3rd, 2016 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations
This CONSENT AND STAND-BY LICENSE AGREEMENT (this “Agreement”) dated as of April 28, 2016 (the “Effective Date”) is entered into among TOKO PHARMACEUTICAL IND. CO., LTD., a Japanese corporation having its principal office at 3-8-19, Shinden, Adachi-ku, Tokyo 123-0865, Japan (“Toko”), SYROS PHARMACEUTICALS, INC., a Delaware corporation having its principal office at 620 Memorial Drive, Suite 300, Cambridge, Massachusetts 02139, USA (“Syros”) and TMRC Co., Ltd., a Japanese corporation having its principal office at 1-12-12, Kita Shinjuku, Shinjuku-ku, Tokyo 164-0074, Japan (“TMRC”).
